CAR-Macrophage efficiently uptakes apoptotic cell and cholesterol crystals via β-cyclodextrin, activating the LXR pathway and promoting cholesterol efflux
Invention Summary:
Atherosclerosis is considered the major cause of cardiovascular disease, leading to ischemic heart disease and ischemic strokes, the 1st and 5th largest causes of death worldwide. Two of the main contributors to atherosclerosis include (1) impaired clearance of apoptotic cells (efferocytosis) and (2) formation of cholesterol crystals which enrich lesion foam cells.
Rutgers researchers have developed a chimeric antigen receptor (CAR) macrophage that targets phagocytosis-resistant apoptotic cells by targeting surface protein CD47. These macrophages have been further modified with reactive oxygen species-responsive nanoparticles which target the liver X receptor (LXR) pathway, a pathway which regulates cholesterol metabolism and homeostasis. This innovative combination stabilizes atherosclerotic plaques and significantly enhances phagocytosis, thus representing a potential new therapy for treating cardiovascular disease.
Market Applications:
- Targeted therapy for treating atherosclerosis
Advantages:
-
Enhances phagocytosis with significantly greater activity compared to standard control macrophages
-
Targets apoptotic cells with elevated CD47 expression
-
High bioavailability of β-cyclodextrin further augments macrophage functions
-
Promotes metabolic reprogramming and improves LXR signaling
Intellectual Property & Development Status: Patent pending. Available for licensing and/or research collaboration. For any business development and other collaborative partnerships contact marketingbd@research.rutgers.edu
Publications: Enhancing CAR Macrophage Efferocytosis via Surface Engineered Lipid Nanoparticles Targeting LXR Signaling. Chuang et.al., Advanced Materials, 2024, 36:2308377 (https://doi.org/10.1002/adma.202308377)
